Indeed, in APP(Swe)/PS1 transgenic AD model mice M-CSF treatment resulted in a reduced number of Aβ deposits, a higher ratio of microglia with evidence of Aβ internalization, and reduced cognitive decline (Boissonneault et al., 2009). The gene discussed is CSF1; the disease is Alzheimer disease.